Marco Fiore Urizar, MD
Endocrinology, Diabetes & Metabolism · Pembroke Pines, FLNPI 1720238074
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.1%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Dexcom, Inc. accounts for 65.5% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $3,717 and has fallen 90.9% since, to $339 in 2025.
Across 61 payments — averaging $86.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$3K
- Sanofi-aventis U.S. LLC$573
- Eli Lilly$349
- Madrigal Pharmaceuticals$161
- Novo Nordisk$159
- Cequr Corporation$117
- plus $453 from 12 others
Across 6 payments — averaging $34,638 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$208K
What the payments were for
- Speaking & faculty fees$2,00038%
- Travel & lodging$1,67732%
- Food & beverage$1,49428%
- Education$240%
- Gifts$591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 3 | $3,443 |
| Sanofi-aventis U.S. LLC | 18 | $573 |
| Eli Lilly | 1 | $349 |
| Madrigal Pharmaceuticals | 2 | $161 |
| Novo Nordisk | 3 | $159 |
| Cequr Corporation | 3 | $117 |
| Amneal Pharmaceuticals LLC | 4 | $63 |
| Mannkind Corporation | 1 | $59 |
| Abbott | 3 | $52 |
| Lilly USA, LLC | 5 | $51 |
| Xeris Pharmaceuticals, Inc. | 3 | $43 |
| Boehringer Ingelheim | 3 | $43 |
| BETA Bionics, Inc. | 5 | $42 |
| Insulet Corporation | 3 | $37 |
| Halozyme Inc | 1 | $21 |
| Tandem Diabetes Care, Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM CGM$3,443
- SOLIQUA 100/33$243
- REZDIFFRA$146
- Ozempic$121
- RYBELSUS$121
- TOUJEO$118
How this compares
$5,254 in reported general payments places this provider in the 55th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $62,720 |
| MounjaroTirzepatide | 45 | $47,564 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $17,315 |
| FarxigaDapagliflozin Propanediol | 11 | $11,558 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $11,064 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 19 | $10,576 |
| Testosterone | 18 | $4,452 |
| SynthroidLevothyroxine Sodium | 26 | $2,483 |
| Comfort Ez Pen NeedlePen Needle, Diabetic | 23 | $1,907 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,768 |
| Levothyroxine Sodium | 105 | $1,664 |
| Hydrocortisone | 23 | $1,358 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $1,091 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 12 | $623 |
| Metformin Hcl | 83 | $538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $159 | $62,72035 claims |
| Lilly USA, LLCMounjaro | $51 | $47,56445 claims |
| Boehringer IngelheimSynjardy Xr | $43 | $10,57619 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $63 | $1,959121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Pembroke Pines
- Fidel HenriquezPembroke Pines$548K
- Andres HenriquezPembroke Pines$136K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.